Detalles de la búsqueda
1.
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.
J Pharmacokinet Pharmacodyn
; 45(6): 803-816, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30377888
2.
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.
J Pharmacokinet Pharmacodyn
; 45(5): 679-691, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29961161
3.
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.
J Pharmacokinet Pharmacodyn
; 45(4): 523-535, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29549540
4.
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.
J Pharmacokinet Pharmacodyn
; 44(5): 437-448, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28634654
5.
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.
J Pharmacokinet Pharmacodyn
; 44(5): 425-436, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28623612
6.
Landmark and longitudinal exposure-response analyses in drug development.
J Pharmacokinet Pharmacodyn
; 44(5): 503-507, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28730565
7.
Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis.
Clin Transl Sci
; 15(3): 749-760, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34854241
8.
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
J Clin Pharmacol
; 62(5): 656-669, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34708423
9.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(4): 433-439, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35749004
10.
Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
Clin Pharmacol Ther
; 109(1): 131-139, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32865226
11.
Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data.
AAPS J
; 22(5): 95, 2020 07 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32696273
12.
Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents.
AAPS J
; 22(4): 79, 2020 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700158
13.
Applying Beta Distribution in Analyzing Bounded Outcome Score Data.
AAPS J
; 22(3): 61, 2020 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32185522
14.
Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Clin Drug Investig
; 40(12): 1127-1136, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33085033
15.
Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
Clin Transl Sci
; 13(6): 1217-1226, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32407591
16.
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.
J Clin Pharmacol
; 60(7): 889-902, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32026499
17.
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
Ther Adv Cardiovasc Dis
; 13: 1753944719863641, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31364490
18.
Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects.
J Clin Pharmacol
; 59(7): 968-978, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30776134
19.
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
J Clin Pharmacol
; 48(1): 73-84, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18025525
20.
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Cancer Chemother Pharmacol
; 62(1): 97-109, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17805538